文献速递神经肿瘤

贝伐珠单抗单药或联合化疗作为复发高级别胶质瘤的后线治疗

Late-line treatment with bevacizumab alone or in combination with chemotherapy in recurrent high-grade gliomas.
PubMed 文献 · Acta Neurochir (Wien) · 2023-02-13

该回顾性研究分析了2010至2022年间31例接受贝伐珠单抗单药或联合化疗作为后线治疗的复发高级别胶质瘤患者,14例(45.2%)按RANO标准为缓解者。3、6、12个月总生存率分别为80.3%、62.1%、43.5,无进展生存率分别为48.4%、34.3%、21.8。多因素分析显示仅贝伐珠单抗启动时增强T1加权MRI上较小的2D肿瘤尺寸与无进展生存独立相关(p=0.02)。

要点

  • 31例复发高级别胶质瘤患者接受贝伐珠单抗单药或联合化疗后线治疗,14例(45.2%)按RANO标准缓解。
  • 3、6、12个月总生存率分别为80.3%、62.1%、43.5,无进展生存率分别为48.4%、34.3%、21.8。
  • 贝伐珠单抗启动时增强T1加权MRI上较小的2D肿瘤尺寸与无进展生存独立相关(p=0.02)。

核心结论

  • 贝伐珠单抗单药或联合化疗作为复发高级别胶质瘤的后线治疗可能对部分患者有益。
  • 贝伐珠单抗启动时增强T1加权MRI上较小的2D肿瘤尺寸与较长的进展时间独立相关。

研究设计与样本

  • 回顾性分析2010年至2022年间31例连续接受贝伐珠单抗单药或联合化疗作为后线治疗的复发高级别胶质瘤患者。
  • 采用Kaplan-Meier曲线分析总生存和无进展生存,采用回归分析评估预后变量对无进展生存的预测价值。

主要发现

  • 31例患者中14例(45.2%)按RANO标准为缓解者,17例(54.8%)为进展或稳定疾病。
  • 3、6、12个月总生存率分别为80.3%、62.1%、43.5,无进展生存率分别为48.4%、34.3%、21.8。
  • 多因素生存分析中,仅贝伐珠单抗启动时增强T1加权MRI上较小的2D肿瘤尺寸与无进展生存独立相关(p=0.02)。
  • MGMT启动子未甲基化组中位进展时间为3个月(95%CI:1-4),甲基化组为6个月(95%CI:1-11),差异无统计学意义(p=0.37)。

临床怎么用

  • 作者认为贝伐珠单抗单药或联合化疗作为后线治疗可能对部分复发高级别胶质瘤患者有益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Bevacizumab's use in recurrent high-grade glioma is controversial. This study evaluates outcomes in recurrent high-grade glioma patients receiving bevacizumab alone or combined with chemotherapy as a late-line treatment. METHODS: We retrospectively analyzed patients treated with bevacizumab alone or combined with chemotherapy for high-grade gliomas who showed tumor progression after multiple treatment attempts. Overall survival (OS) and progression-free survival (PFS) were analyzed with Kaplan-Meier curves. Predictors of PFS according to prognostic variables were assessed with regression analysis. RESULTS: Between 2010 and 2022, 31 consecutive patients received bevacizumab alone or combined with chemotherapy as a late-line treatment for recurrent high-grade gliomas. Of these patients, 14 (45.2%) were responders according to RANO criteria, and 17 (54.8%) showed progressive or stable disease. OS at 3, 6, and 12 months was 80.3%, 62.1%, and 43.5. PFS was 48.4%, 34.3%, and 21.8%, respectively. In the multivariate survival analysis, the only factor independently associated with PFS was smaller 2D tumor size in post-contrast T1-weighted MRI at bevacizumab initiation (p = 0.02). Median time-to-progression was 3 months (95%CI: 1-4) in the unmethylated MGMT promoter group and 6 (95%CI: 1-11) in the methylated MGMT promoter group. This difference was not statistically significant (p = 0.37). CONCLUSIONS: Bevacizumab alone or in combination with chemotherapy could be beneficial as a late-line therapy in a subset of patients with recurrent high-grade glioma. Small 2D tumor size in post-contrast T1 weighted MRI at bevacizumab initiation was independently associated with prolonged time to progression.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Yahia-Cherif M, Luce S, De Witte O, et al. Late-line treatment with bevacizumab alone or in combination with chemotherapy in recurrent high-grade gliomas. Acta Neurochir (Wien). 2023. PMID: 36781461. doi:10.1007/s00701-023-05524-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。